Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198279 | 0.95 | L3MBTL1 (0.44) | L3MBTL1PTGS2ALDH1A1MAPTALOX15 | |
| SCHEMBL5197827 | 0.94 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1MAPTALOX15HSD17B10 | |
| SCHEMBL5198805 | 0.91 | MAPK1 (0.41) | L3MBTL1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL5197430 | 0.90 | L3MBTL1 (0.36) | L3MBTL1PTGS2ALDH1A1MAPTALOX15 | |
| SCHEMBL5197342 | 0.90 | HPGD (0.41) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL5197401 | 0.90 | ALDH1A1 (0.39) | L3MBTL1PTGS2ALDH1A1KDM4EHPGD | |
| SCHEMBL5199033 | 0.90 | L3MBTL1 (0.38) | L3MBTL1PTGS2ALDH1A1MAPTALOX15 | |
| SCHEMBL5222994 | 0.90 | L3MBTL1 (0.38) | L3MBTL1PTGS2ALDH1A1MAPTALOX15 | |
| SCHEMBL5222794 | 0.90 | NR1H4 (0.36) | L3MBTL1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL5197025 | 0.89 | BRD4 (0.36) | ALDH1A1KDM4EGAAGRIN2BSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | L3MBTL1 1887/4885PTGS2 2807/4885ALDH1A1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.